Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Omrix on Top: Fool by Numbers

By Motley Fool Contributors - Updated Nov 15, 2016 at 12:55AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Fast facts the Fool way.

On March 8, Omrix Biopharmaceuticals (NASDAQ:OMRI) released fourth-quarter earnings for the period ended Dec. 31.

  • The top line was up more than 100%, thanks to an increase in unit sales of Evicel and Quixil.
  • A stock offering helped raise cash and cash equivalents by $80.8 million. This led to a 44% increase in diluted share count.
  • The FDA accepted the company's Investigational New Drug application for Adhexil, an anti-adhesion product candidate, allowing the initiation of clinical trials.
  • For year 2007, product sales are expected to be in range of $50 million to $55 million. This is slightly lower than 2006 product sales of $57 million.

(Figures in thousands, except per-share data)

Income Statement Highlights

Q4 2006

Q4 2005

Change

Sales

$18,044

$8,328

116.7%

Net Profit

$6,390

$93

6771.0%

EPS

$0.41

$0.01

4000.0%

Diluted Shares

15,601.2

10,871.3

43.5%



Get back to basics with a look at the income statement.

Margin Checkup

Q4 2006

Q4 2005

Change*

Gross Margin

50.5%

30.6%

19.8

Operating Margin

30.6%

7.6%

23.0

Net Margin

35.4%

1.1%

34.3

*Expressed in percentage points.

Margins are the earnings engine.

Balance Sheet Highlights

Assets

Q4 2006

Q4 2005

Change

Cash + ST Invest.

$80,822

$6,494

1144.6%

Accounts Rec.

$9,748

$5,344

82.4%

Inventory

$17,419

$6,793

156.4%



Liabilities

Q4 2006

Q4 2005

Change

Accounts Payable*

$7,498

$5,995

25.1%

Long-Term Debt

$394

$6,026

(93.5%)

*Accounts payable includes accrued liabilities.

The balance sheet reflects the company's health.

Cash Flow Highlights

Cash flow data is not available.

Free cash flow is a Fool's best friend.

Related Foolishness:

Omrix Biopharmaceuticals is a Rule Breakers recommendation. A free 30-day trial to the newsletter will let you find out why.

Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.